Homology Medicines Inc. Stock News

Homology Medicines (FIXX) delivered earnings and revenue surprises of 10.53% and 23.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences:

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "C

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Homology Medicines, In

Homology Medicines (FIXX) delivered earnings and revenue surprises of 20% and 38.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

After losing some value lately, a hammer chart pattern has been formed for Homology Medicines (FIXX), indicating that the stock has found support. This, combined with an upward trend in earnings estim

Homology Medicines (FIXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Homology Medicines (FIXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BEDFORD, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation at the following virtual investor conferences:

Gainers Mullen Automotive, Inc. (NASDAQ: MULN ) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group, Inc. (NASDAQ: REGI ) shares jumped 38.7% to $60.75 after Chevron Corp (NYSE: CVX ) announced an agreement to acquire the company. IntriCon Corporation (NASDAQ: IIN ) gained 37.3% to $23.91 after the company agreed to be acquired by an affiliate of Altaris Capital Partners for $241 million. IntriCon also posted Q4 EPS of $0.23. NeuroSense Therapeutics Ltd. (NASDAQ: NRSN ) climbed 30.5% to $2.01 after gaining around 8% on Friday. First Horizon Corporation (NYSE: FHN ) shares climbed 30.4% to $23.80 after TD announced acquisition of the company for $25 per share in cash. Imperial Petroleum Inc. (NASDAQ: IMPP ) shares rose 26% to $2.6450 after jumping around 34% on Friday. Everbridge, Inc. (NASDAQ: EVBG ) gained 23% to $37.67. Lifeway Foods, Inc. (NASDAQ: LWAY ) surged 20% to $6.60. Azure Power Global Limited (NYSE: AZRE ) gained 19.9% to $18.76.

Homology Medicines (FIXX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in

Over the past 3 months, 4 analysts have published their opinion on Homology Medicines (NASDAQ: FIXX ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 1 0 0 Last 30D 3 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Homology Medicines. The company has an average price target of $14.25 with a high of $29.00 and a low of $4.00. Below is a summary of how these 4 analysts rated Full story available on Benzinga.com

Oppenheimer has downgraded Homology Medicines (FIXX) to perform following the company''s announcement that the FDA imposed a clinical hold on its pheNIX gene therapy trial of HMI-102.

HOOKIPA Pharma HOOK +18%. Nuvectis Pharma (NVCT) +16%. Allarity Therapeutics (ALLR) -29%. Homology Medicines FIXX -27%.